BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sockolosky JT, Szoka FC. The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy. Adv Drug Deliv Rev 2015;91:109-24. [PMID: 25703189 DOI: 10.1016/j.addr.2015.02.005] [Cited by in Crossref: 106] [Cited by in F6Publishing: 97] [Article Influence: 15.1] [Reference Citation Analysis]
Number Citing Articles
1 Mukai H, Watanabe Y. Review: PET imaging with macro- and middle-sized molecular probes. Nucl Med Biol 2021;92:156-70. [PMID: 32660789 DOI: 10.1016/j.nucmedbio.2020.06.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Jefferis R. Recombinant Proteins and Monoclonal Antibodies. In: Rapp E, Reichl U, editors. Advances in Glycobiotechnology. Cham: Springer International Publishing; 2021. pp. 281-318. [DOI: 10.1007/10_2017_32] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Fieux M, Le Quellec S, Bartier S, Coste A, Louis B, Giroudon C, Nourredine M, Bequignon E. FcRn as a Transporter for Nasal Delivery of Biologics: A Systematic Review. Int J Mol Sci 2021;22:6475. [PMID: 34204226 DOI: 10.3390/ijms22126475] [Reference Citation Analysis]
4 Martins JP, Kennedy PJ, Santos HA, Barrias C, Sarmento B. A comprehensive review of the neonatal Fc receptor and its application in drug delivery. Pharmacol Ther 2016;161:22-39. [PMID: 27016466 DOI: 10.1016/j.pharmthera.2016.03.007] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 10.2] [Reference Citation Analysis]
5 Woodham AW, Zeigler SH, Zeyang EL, Kolifrath SC, Cheloha RW, Rashidian M, Chaparro RJ, Seidel RD, Garforth SJ, Dearling JL, Mesyngier M, Duddempudi PK, Packard AB, Almo SC, Ploegh HL. In vivo detection of antigen-specific CD8+ T cells by immuno-positron emission tomography. Nat Methods 2020;17:1025-32. [PMID: 32929269 DOI: 10.1038/s41592-020-0934-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
6 Balibegloo M, Rezaei N. Development and clinical application of bispecific antibody in the treatment of colorectal cancer. Expert Rev Clin Immunol 2020;16:689-709. [PMID: 32536227 DOI: 10.1080/1744666X.2020.1783249] [Reference Citation Analysis]
7 Martins JP, Figueiredo P, Wang S, Espo E, Celi E, Martins B, Kemell M, Moslova K, Mäkilä E, Salonen J, Kostiainen MA, Celia C, Cerullo V, Viitala T, Sarmento B, Hirvonen J, Santos HA. Neonatal Fc receptor-targeted lignin-encapsulated porous silicon nanoparticles for enhanced cellular interactions and insulin permeation across the intestinal epithelium. Bioact Mater 2022;9:299-315. [PMID: 34820572 DOI: 10.1016/j.bioactmat.2021.08.007] [Reference Citation Analysis]
8 Hasan MN, Hwang YH, An JM, Shahriar SMS, Cho S, Lee YK. Oral GLP1 Gene Delivery by an Antibody-Guided Nanomaterial to Treat Type 2 Diabetes Mellitus. ACS Appl Mater Interfaces 2020;12:38925-35. [PMID: 32805914 DOI: 10.1021/acsami.0c09814] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
9 Ma Y, Ke C, Wan Z, Li Z, Cheng X, Wang X, Zhao J, Ma Y, Ren L, Han H, Zhao Y. Truncation of the Murine Neonatal Fc Receptor Cytoplasmic Tail Does Not Alter IgG Metabolism or Transport In Vivo. J Immunol 2018;200:1413-24. [PMID: 29298832 DOI: 10.4049/jimmunol.1700924] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
10 Rachmin I, O'Meara CC, Ricci-Blair EM, Feng Y, Christensen EM, Duffy JF, Zitting KM, Czeisler CA, Pancoast JR, Cannon CP, O'Donoghue ML, Morrow DA, Lee RT. Soluble interleukin-13rα1: a circulating regulator of glucose. Am J Physiol Endocrinol Metab 2017;313:E663-71. [PMID: 28874358 DOI: 10.1152/ajpendo.00168.2017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
11 Zhang Q, Qian M, Wu Y, Wang Y, Shangguan W, Lu J, Zhao W, Feng J. Design and biological evaluation of novel long-acting adalimumab Fab conjugated with the albumin binding domain. Eur J Pharmacol 2021;904:174152. [PMID: 33964292 DOI: 10.1016/j.ejphar.2021.174152] [Reference Citation Analysis]
12 Frich CK, Krüger F, Walther R, Domar C, Andersen AHF, Tvilum A, Dagnæs-Hansen F, Denton PW, Tolstrup M, Paludan SR, Münch J, Zelikin AN. Non-covalent hitchhiking on endogenous carriers as a protraction mechanism for antiviral macromolecular prodrugs. J Control Release 2019;294:298-310. [PMID: 30552954 DOI: 10.1016/j.jconrel.2018.12.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
13 Sánchez A, Mejía SP, Orozco J. Recent Advances in Polymeric Nanoparticle-Encapsulated Drugs against Intracellular Infections. Molecules 2020;25:E3760. [PMID: 32824757 DOI: 10.3390/molecules25163760] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
14 Ingram JR, Blomberg OS, Sockolosky JT, Ali L, Schmidt FI, Pishesha N, Espinosa C, Dougan SK, Garcia KC, Ploegh HL, Dougan M. Localized CD47 blockade enhances immunotherapy for murine melanoma. Proc Natl Acad Sci U S A 2017;114:10184-9. [PMID: 28874561 DOI: 10.1073/pnas.1710776114] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 10.8] [Reference Citation Analysis]
15 Lucas AT, Price LSL, Schorzman AN, Storrie M, Piscitelli JA, Razo J, Zamboni WC. Factors Affecting the Pharmacology of Antibody-Drug Conjugates. Antibodies (Basel) 2018;7:E10. [PMID: 31544862 DOI: 10.3390/antib7010010] [Cited by in Crossref: 38] [Cited by in F6Publishing: 25] [Article Influence: 9.5] [Reference Citation Analysis]
16 Xiao Y, Tang Z, Wang J, Liu C, Kong N, Farokhzad OC, Tao W. Plattformen für die orale Insulinabgabe: Strategien zur Beseitigung der biologischen Barrieren. Angew Chem 2020;132:19955-64. [DOI: 10.1002/ange.202008879] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Ling LE, Hillson JL, Tiessen RG, Bosje T, van Iersel MP, Nix DJ, Markowitz L, Cilfone NA, Duffner J, Streisand JB, Manning AM, Arroyo S. M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human Study. Clin Pharmacol Ther 2019;105:1031-9. [PMID: 30402880 DOI: 10.1002/cpt.1276] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 10.8] [Reference Citation Analysis]
18 Blundell PA, Lu D, Wilkinson M, Dell A, Haslam S, Pleass RJ. Insertion of N-Terminal Hinge Glycosylation Enhances Interactions of the Fc Region of Human IgG1 Monomers with Glycan-Dependent Receptors and Blocks Hemagglutination by the Influenza Virus. J Immunol 2019;202:1595-611. [PMID: 30683699 DOI: 10.4049/jimmunol.1801337] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
19 Podust VN, Balan S, Sim BC, Coyle MP, Ernst U, Peters RT, Schellenberger V. Extension of in vivo half-life of biologically active molecules by XTEN protein polymers. J Control Release 2016;240:52-66. [PMID: 26497931 DOI: 10.1016/j.jconrel.2015.10.038] [Cited by in Crossref: 68] [Cited by in F6Publishing: 57] [Article Influence: 9.7] [Reference Citation Analysis]
20 Xiao Y, Tang Z, Wang J, Liu C, Kong N, Farokhzad OC, Tao W. Oral Insulin Delivery Platforms: Strategies To Address the Biological Barriers. Angew Chem Int Ed 2020;59:19787-95. [DOI: 10.1002/anie.202008879] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
21 Oh J, Huh KY, Cho YG, Cha JE, Kim SJ, Yoon SH, Park SS, Yoon H, Lee J, Lee H. Safety, tolerability and pharmacokinetics and pharmacodynamics of HL2351, a novel hybrid fc-fused interleukin-1 receptor antagonist, in healthy subjects: A first-in-human study. Br J Clin Pharmacol 2020;86:372-9. [PMID: 31658396 DOI: 10.1111/bcp.14161] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
22 Hintersteiner B, Lingg N, Zhang P, Woen S, Hoi KM, Stranner S, Wiederkum S, Mutschlechner O, Schuster M, Loibner H, Jungbauer A. Charge heterogeneity: Basic antibody charge variants with increased binding to Fc receptors. MAbs 2016;8:1548-60. [PMID: 27559765 DOI: 10.1080/19420862.2016.1225642] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 6.8] [Reference Citation Analysis]
23 Tan H, Su W, Zhang W, Wang P, Sattler M, Zou P. Recent Advances in Half-life Extension Strategies for Therapeutic Peptides and Proteins. Curr Pharm Des 2018;24:4932-46. [PMID: 30727869 DOI: 10.2174/1381612825666190206105232] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
24 Qi T, Cao Y. In Translation: FcRn across the Therapeutic Spectrum. Int J Mol Sci 2021;22:3048. [PMID: 33802650 DOI: 10.3390/ijms22063048] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
25 Morosky S, Wells AI, Lemon K, Evans AS, Schamus S, Bakkenist CJ, Coyne CB. The neonatal Fc receptor is a pan-echovirus receptor. Proc Natl Acad Sci U S A 2019;116:3758-63. [PMID: 30808762 DOI: 10.1073/pnas.1817341116] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
26 Jordan SC, Ammerman N, Vo A. Implications of Fc Neonatal Receptor (FcRn) Manipulations for Transplant Immunotherapeutics. Transplantation 2020;104:17-23. [PMID: 31397806 DOI: 10.1097/TP.0000000000002912] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
27 Lee SW, Choi D, Heo M, Shin EC, Park SH, Kim SJ, Oh YK, Lee BH, Yang SH, Sung YC, Lee H. hIL-7-hyFc, A Long-Acting IL-7, Increased Absolute Lymphocyte Count in Healthy Subjects. Clin Transl Sci 2020;13:1161-9. [PMID: 32339447 DOI: 10.1111/cts.12800] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
28 Wang Q, Xie X, Su F, Wang J, Chen S, Wang Q, Jiang D, Wang Y, Zhang T, Liu C, Han M, Tao T, Wu Q, Xi N, Li Z, Song H, Fang Y. A randomized controlled dose-escalation study of SSS07, a humanized rabbit anti-human TNF alpha antibody, in healthy Chinese adults. International Immunopharmacology 2019;75:105807. [DOI: 10.1016/j.intimp.2019.105807] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Nagata S, Yamasaki M, Kawano A, Kitamura K. Developments of human adrenomedullin-IgG1 Fc fusion proteins. The Journal of Biochemistry 2019;166:157-62. [DOI: 10.1093/jb/mvz023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
30 Cavaco M, Castanho MARB, Neves V. Peptibodies: An elegant solution for a long-standing problem. Peptide Science 2018;110:e23095. [DOI: 10.1002/bip.23095] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
31 Wonnacott A, Denby L, Jm Coward R, Fraser DJ, Bowen T. MicroRNAs and Their Delivery in Diabetic Fibrosis. Adv Drug Deliv Rev 2021;:114045. [PMID: 34767865 DOI: 10.1016/j.addr.2021.114045] [Reference Citation Analysis]
32 Kim YJ, Ertan-Ahmed S, Capan Y, Yang SI. Preclinical evaluation of a biobetter candidate: Pharmacokinetics and pharmacodynamics of GX-G3 in healthy and neutropenia-induced rats. Drug Dev Res 2019;80:807-13. [PMID: 31294492 DOI: 10.1002/ddr.21563] [Reference Citation Analysis]
33 Kelsall BL. Mucosal Antigen Sampling Across the Villus Epithelium by Epithelial and Myeloid Cells. Mucosal Vaccines. Elsevier; 2020. pp. 55-69. [DOI: 10.1016/b978-0-12-811924-2.00003-1] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Deng F, Bae YH. Bile acid transporter-mediated oral drug delivery. J Control Release 2020;327:100-16. [PMID: 32711025 DOI: 10.1016/j.jconrel.2020.07.034] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
35 Saunders KO. Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life. Front Immunol 2019;10:1296. [PMID: 31231397 DOI: 10.3389/fimmu.2019.01296] [Cited by in Crossref: 78] [Cited by in F6Publishing: 78] [Article Influence: 26.0] [Reference Citation Analysis]
36 Chen X, Li D, Cao Y, Gao J, Jin H, Shan H. Early Therapeutic Vaccination Prediction of Hepatocellular Carcinoma via Imaging OX40-Mediated Tumor Infiltrating Lymphocytes. Mol Pharm 2019;16:4252-9. [PMID: 31454248 DOI: 10.1021/acs.molpharmaceut.9b00590] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
37 Kim H, Jang H, Cho H, Choi J, Hwang KY, Choi Y, Kim SH, Yang Y. Recent Advances in Exosome-Based Drug Delivery for Cancer Therapy. Cancers (Basel) 2021;13:4435. [PMID: 34503245 DOI: 10.3390/cancers13174435] [Reference Citation Analysis]
38 Lucas AT, Moody A, Schorzman AN, Zamboni WC. Importance and Considerations of Antibody Engineering in Antibody-Drug Conjugates Development from a Clinical Pharmacologist's Perspective. Antibodies (Basel) 2021;10:30. [PMID: 34449544 DOI: 10.3390/antib10030030] [Reference Citation Analysis]
39 Smith AAA, Zuwala K, Pilgram O, Johansen KS, Tolstrup M, Dagnæs-hansen F, Zelikin AN. Albumin–Polymer–Drug Conjugates: Long Circulating, High Payload Drug Delivery Vehicles. ACS Macro Lett 2016;5:1089-94. [DOI: 10.1021/acsmacrolett.6b00544] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
40 Ilieva KM, Fazekas-Singer J, Achkova DY, Dodev TS, Mele S, Crescioli S, Bax HJ, Cheung A, Karagiannis P, Correa I, Figini M, Marlow R, Josephs DH, Beavil AJ, Maher J, Spicer JF, Jensen-Jarolim E, Tutt AN, Karagiannis SN. Functionally Active Fc Mutant Antibodies Recognizing Cancer Antigens Generated Rapidly at High Yields. Front Immunol 2017;8:1112. [PMID: 28959256 DOI: 10.3389/fimmu.2017.01112] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
41 Zuwala K, Riber CF, Løvschall KB, Andersen AHF, Sørensen L, Gajda P, Tolstrup M, Zelikin AN. Macromolecular prodrugs of ribavirin: Polymer backbone defines blood safety, drug release, and efficacy of anti-inflammatory effects. J Control Release 2018;275:53-66. [PMID: 29432822 DOI: 10.1016/j.jconrel.2018.02.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
42 Jing X, Hou Y, Hallett W, Sahajwalla CG, Ji P. Key Physicochemical Characteristics Influencing ADME Properties of Therapeutic Proteins. Adv Exp Med Biol 2019;1148:115-29. [PMID: 31482497 DOI: 10.1007/978-981-13-7709-9_6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
43 Li Y, Li R, Wang M, Liu Y, Yin Y, Zai X, Song X, Chen Y, Xu J, Chen W. Fc-Based Recombinant Henipavirus Vaccines Elicit Broad Neutralizing Antibody Responses in Mice. Viruses 2020;12:E480. [PMID: 32340278 DOI: 10.3390/v12040480] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
44 Kariolis MS, Wells RC, Getz JA, Kwan W, Mahon CS, Tong R, Kim DJ, Srivastava A, Bedard C, Henne KR, Giese T, Assimon VA, Chen X, Zhang Y, Solanoy H, Jenkins K, Sanchez PE, Kane L, Miyamoto T, Chew KS, Pizzo ME, Liang N, Calvert MEK, DeVos SL, Baskaran S, Hall S, Sweeney ZK, Thorne RG, Watts RJ, Dennis MS, Silverman AP, Zuchero YJY. Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys. Sci Transl Med 2020;12:eaay1359. [PMID: 32461332 DOI: 10.1126/scitranslmed.aay1359] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 46.0] [Reference Citation Analysis]
45 Park HI, Yoon HW, Jung ST. The Highly Evolvable Antibody Fc Domain. Trends in Biotechnology 2016;34:895-908. [DOI: 10.1016/j.tibtech.2016.04.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
46 Xu Y, Shrestha N, Préat V, Beloqui A. Overcoming the intestinal barrier: A look into targeting approaches for improved oral drug delivery systems. Journal of Controlled Release 2020;322:486-508. [DOI: 10.1016/j.jconrel.2020.04.006] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 14.0] [Reference Citation Analysis]
47 Choi AY, Manook M, Olaso D, Ezekian B, Park J, Freischlag K, Jackson A, Knechtle S, Kwun J. Emerging New Approaches in Desensitization: Targeted Therapies for HLA Sensitization. Front Immunol 2021;12:694763. [PMID: 34177960 DOI: 10.3389/fimmu.2021.694763] [Reference Citation Analysis]
48 Fonseca MHG, Furtado GP, Bezerra MRL, Pontes LQ, Fernandes CFC. Boosting half-life and effector functions of therapeutic antibodies by Fc-engineering: An interaction-function review. International Journal of Biological Macromolecules 2018;119:306-11. [DOI: 10.1016/j.ijbiomac.2018.07.141] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
49 Unverdorben F, Richter F, Hutt M, Seifert O, Malinge P, Fischer N, Kontermann RE. Pharmacokinetic properties of IgG and various Fc fusion proteins in mice. MAbs 2016;8:120-8. [PMID: 26514880 DOI: 10.1080/19420862.2015.1113360] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 8.3] [Reference Citation Analysis]
50 Li L, Yang J, Soodvilai S, Wang J, Opanasopit P, Kopeček J. Drug-free albumin-triggered sensitization of cancer cells to anticancer drugs. J Control Release 2019;293:84-93. [PMID: 30465822 DOI: 10.1016/j.jconrel.2018.11.015] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
51 Mucke HA. Patent highlights August-September 2016. Pharm Pat Anal 2017;6:17-24. [PMID: 28155581 DOI: 10.4155/ppa-2016-0037] [Reference Citation Analysis]
52 Svilenov HL, Sacherl J, Reiter A, Wolff LS, Cheng CC, Stern M, Grass V, Feuerherd M, Wachs FP, Simonavicius N, Pippig S, Wolschin F, Keppler OT, Buchner J, Brockmeyer C, Protzer U. Picomolar inhibition of SARS-CoV-2 variants of concern by an engineered ACE2-IgG4-Fc fusion protein. Antiviral Res 2021;196:105197. [PMID: 34774603 DOI: 10.1016/j.antiviral.2021.105197] [Reference Citation Analysis]
53 Fejerskov B, Jarlstad Olesen MT, Zelikin AN. Substrate mediated enzyme prodrug therapy. Advanced Drug Delivery Reviews 2017;118:24-34. [DOI: 10.1016/j.addr.2017.04.013] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
54 Amadou Amani S, Lang GA, Ballard JD, Lang ML. The murine neonatal Fc receptor is required for transport of immunization-induced C. difficile-specific IgG to the gut and protection against disease but does not affect disease susceptibility. Infect Immun 2021;:IAI0027421. [PMID: 34097471 DOI: 10.1128/IAI.00274-21] [Reference Citation Analysis]
55 Fan XX, Xu MZ, Leung EL, Jun C, Yuan Z, Liu L. ROS-Responsive Berberine Polymeric Micelles Effectively Suppressed the Inflammation of Rheumatoid Arthritis by Targeting Mitochondria. Nanomicro Lett 2020;12:76. [PMID: 34138288 DOI: 10.1007/s40820-020-0410-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
56 Ladel S, Maigler F, Flamm J, Schlossbauer P, Handl A, Hermann R, Herzog H, Hummel T, Mizaikoff B, Schindowski K. Impact of Glycosylation and Species Origin on the Uptake and Permeation of IgGs through the Nasal Airway Mucosa. Pharmaceutics 2020;12:E1014. [PMID: 33114132 DOI: 10.3390/pharmaceutics12111014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
57 Hirosue S, Dubrot J. Modes of Antigen Presentation by Lymph Node Stromal Cells and Their Immunological Implications. Front Immunol 2015;6:446. [PMID: 26441957 DOI: 10.3389/fimmu.2015.00446] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.1] [Reference Citation Analysis]
58 Bteich M, Poulin P, Haddad S. The potential protein-mediated hepatic uptake: discussion on the molecular interactions between albumin and the hepatocyte cell surface and their implications for the in vitro-to-in vivo extrapolations of hepatic clearance of drugs. Expert Opinion on Drug Metabolism & Toxicology 2019;15:633-58. [DOI: 10.1080/17425255.2019.1640679] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
59 Liu X, Palaniyandi S, Zhu I, Tang J, Li W, Wu X, Ochsner SP, Pauza CD, Cohen JI, Zhu X. Human cytomegalovirus evades antibody-mediated immunity through endoplasmic reticulum-associated degradation of the FcRn receptor. Nat Commun 2019;10:3020. [PMID: 31289263 DOI: 10.1038/s41467-019-10865-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
60 Song X, Li R, Deng H, Li Y, Cui Y, Zhang H, Dai W, He B, Zheng Y, Wang X, Zhang Q. Receptor mediated transcytosis in biological barrier: The influence of receptor character and their ligand density on the transmembrane pathway of active-targeting nanocarriers. Biomaterials 2018;180:78-90. [PMID: 30025247 DOI: 10.1016/j.biomaterials.2018.07.006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
61 Lucas AT, Robinson R, Schorzman AN, Piscitelli JA, Razo JF, Zamboni WC. Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients. Antibodies (Basel) 2019;8:E3. [PMID: 31544809 DOI: 10.3390/antib8010003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
62 Ovacik M, Lin K. Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development. Clin Transl Sci 2018;11:540-52. [PMID: 29877608 DOI: 10.1111/cts.12567] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 12.5] [Reference Citation Analysis]
63 Bequignon E, Dhommée C, Angely C, Thomas L, Bottier M, Escudier E, Isabey D, Coste A, Louis B, Papon JF, Gouilleux-Gruart V. FcRn-Dependent Transcytosis of Monoclonal Antibody in Human Nasal Epithelial Cells In Vitro: A Prerequisite for a New Delivery Route for Therapy? Int J Mol Sci 2019;20:E1379. [PMID: 30893823 DOI: 10.3390/ijms20061379] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
64 Zhang L, Fang Y, Li L, Yang J, Radford DC, Kopeček J. Human Serum Albumin‐Based Drug‐Free Macromolecular Therapeutics: Apoptosis Induction by Coiled‐Coil‐Mediated Cross‐Linking of CD20 Antigens on Lymphoma B Cell Surface. Macromol Biosci 2018;18:1800224. [DOI: 10.1002/mabi.201800224] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
65 Jarlstad Olesen MT, Walther R, Poier PP, Dagnæs‐hansen F, Zelikin AN. Molecular, Macromolecular, and Supramolecular Glucuronide Prodrugs: Lead Identified for Anticancer Prodrug Monotherapy. Angew Chem Int Ed 2020;59:7390-6. [DOI: 10.1002/anie.201916124] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
66 Shen X, Li Q, Wang F, Bao J, Dai M, Zheng H, Lao X. Generation of a novel long-acting thymosin alpha1-Fc fusion protein and its efficacy for the inhibition of breast cancer in vivo. Biomedicine & Pharmacotherapy 2018;108:610-7. [DOI: 10.1016/j.biopha.2018.09.064] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
67 Zhang Y, Li M, Du G, Chen X, Sun X. Advancedoral vaccine delivery strategies for improving the immunity. Adv Drug Deliv Rev 2021;177:113928. [PMID: 34411689 DOI: 10.1016/j.addr.2021.113928] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Wada R, Matsui M, Kawasaki N. Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms. MAbs 2019;11:350-72. [PMID: 30466347 DOI: 10.1080/19420862.2018.1551044] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 14.3] [Reference Citation Analysis]
69 Kim K, Araujo P, Hebbar N, Zhou Z, Zheng X, Zheng F, Rangnekar VM, Zhan CG. Development of a novel prostate apoptosis response-4 (Par-4) protein entity with an extended duration of action for therapeutic treatment of cancer. Protein Eng Des Sel 2019;32:159-66. [PMID: 31711233 DOI: 10.1093/protein/gzz034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
70 Mandal A, Pal D, Agrahari V, Trinh HM, Joseph M, Mitra AK. Ocular delivery of proteins and peptides: Challenges and novel formulation approaches. Adv Drug Deliv Rev 2018;126:67-95. [PMID: 29339145 DOI: 10.1016/j.addr.2018.01.008] [Cited by in Crossref: 69] [Cited by in F6Publishing: 67] [Article Influence: 17.3] [Reference Citation Analysis]
71 Weber T, Bötticher B, Arndt MA, Mier W, Sauter M, Exner E, Keller A, Krämer S, Leotta K, Wischnjow A, Grosse-hovest L, Strumberg D, Jäger D, Gröne H, Haberkorn U, Brem G, Krauss J. Preclinical evaluation of a diabody-based 177Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy in a non-Hodgkin lymphoma mouse model. Cancer Letters 2016;381:296-304. [DOI: 10.1016/j.canlet.2016.08.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
72 Glassman PM, Hood ED, Ferguson LT, Zhao Z, Siegel DL, Mitragotri S, Brenner JS, Muzykantov VR. Red blood cells: The metamorphosis of a neglected carrier into the natural mothership for artificial nanocarriers. Adv Drug Deliv Rev 2021;178:113992. [PMID: 34597748 DOI: 10.1016/j.addr.2021.113992] [Reference Citation Analysis]
73 Jarlstad Olesen MT, Walther R, Poier PP, Dagnæs‐hansen F, Zelikin AN. Molecular, Macromolecular, and Supramolecular Glucuronide Prodrugs: Lead Identified for Anticancer Prodrug Monotherapy. Angew Chem 2020;132:7460-6. [DOI: 10.1002/ange.201916124] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Riber CF, Zelikin AN. Recent advances in macromolecular prodrugs. Current Opinion in Colloid & Interface Science 2017;31:1-9. [DOI: 10.1016/j.cocis.2017.06.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 4.4] [Reference Citation Analysis]
75 Yousefpour P, Ahn L, Tewksbury J, Saha S, Costa SA, Bellucci JJ, Li X, Chilkoti A. Conjugate of Doxorubicin to Albumin-Binding Peptide Outperforms Aldoxorubicin. Small 2019;15:e1804452. [PMID: 30756483 DOI: 10.1002/smll.201804452] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
76 Wyckoff SL, Hudson KE. Targeting the neonatal Fc receptor (FcRn) to treat autoimmune diseases and maternal-fetal immune cytopenias. Transfusion 2021;61:1350-4. [PMID: 33650699 DOI: 10.1111/trf.16341] [Reference Citation Analysis]
77 Kontermann RE. Half-life extended biotherapeutics. Expert Opin Biol Ther 2016;16:903-15. [PMID: 26967759 DOI: 10.1517/14712598.2016.1165661] [Cited by in Crossref: 88] [Cited by in F6Publishing: 80] [Article Influence: 14.7] [Reference Citation Analysis]
78 Zaghmi A, Drouin-Ouellet J, Brambilla D, Gauthier MA. Treating brain diseases using systemic parenterally-administered protein therapeutics: Dysfunction of the brain barriers and potential strategies. Biomaterials 2021;269:120461. [PMID: 33218788 DOI: 10.1016/j.biomaterials.2020.120461] [Reference Citation Analysis]
79 Castleman JS, Moise KJ Jr, Kilby MD. Medical therapy to attenuate fetal anaemia in severe maternal red cell alloimmunisation. Br J Haematol 2021;192:425-32. [PMID: 32794242 DOI: 10.1111/bjh.17041] [Reference Citation Analysis]
80 McCright JC, Maisel K. Engineering drug delivery systems to overcome mucosal barriers for immunotherapy and vaccination. Tissue Barriers 2020;8:1695476. [PMID: 31775577 DOI: 10.1080/21688370.2019.1695476] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
81 Brinkmann U, Kontermann RE. The making of bispecific antibodies. MAbs 2017;9:182-212. [PMID: 28071970 DOI: 10.1080/19420862.2016.1268307] [Cited by in Crossref: 370] [Cited by in F6Publishing: 339] [Article Influence: 74.0] [Reference Citation Analysis]
82 Bam R, Laffey M, Nottberg K, Lown PS, Hackel BJ, Wilson KE. Affibody-Indocyanine Green Based Contrast Agent for Photoacoustic and Fluorescence Molecular Imaging of B7-H3 Expression in Breast Cancer. Bioconjug Chem 2019;30:1677-89. [PMID: 31082216 DOI: 10.1021/acs.bioconjchem.9b00239] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
83 Mao-Draayer Y, Thiel S, Mills EA, Chitnis T, Fabian M, Katz Sand I, Leite MI, Jarius S, Hellwig K. Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations. Nat Rev Neurol 2020;16:154-70. [PMID: 32080393 DOI: 10.1038/s41582-020-0313-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 10.5] [Reference Citation Analysis]
84 Qin JJ, Wang W, Sarkar S, Zhang R. Oral delivery of anti-MDM2 inhibitor SP141-loaded FcRn-targeted nanoparticles to treat breast cancer and metastasis. J Control Release 2016;237:101-14. [PMID: 27394681 DOI: 10.1016/j.jconrel.2016.07.008] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
85 Miyazaki T, Okada K, Yamashita T, Miyazaki M. Two-dimensional gas chromatography time-of-flight mass spectrometry-based serum metabolic fingerprints of neonatal calves before and after first colostrum ingestion. Journal of Dairy Science 2017;100:4354-64. [DOI: 10.3168/jds.2017-12557] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
86 Villa CH, Cines DB, Siegel DL, Muzykantov V. Erythrocytes as Carriers for Drug Delivery in Blood Transfusion and Beyond. Transfus Med Rev 2017;31:26-35. [PMID: 27707522 DOI: 10.1016/j.tmrv.2016.08.004] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 7.0] [Reference Citation Analysis]
87 Yu M, Wu J, Shi J, Farokhzad OC. Nanotechnology for protein delivery: Overview and perspectives. J Control Release 2016;240:24-37. [PMID: 26458789 DOI: 10.1016/j.jconrel.2015.10.012] [Cited by in Crossref: 178] [Cited by in F6Publishing: 158] [Article Influence: 25.4] [Reference Citation Analysis]
88 Yap DYH, Hai J, Lee PCH, Zhou X, Lee M, Zhang Y, Wang M, Chen X. Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers. Clin Transl Sci 2021;14:1769-79. [PMID: 33742786 DOI: 10.1111/cts.13019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
89 Walther R, Rautio J, Zelikin AN. Prodrugs in medicinal chemistry and enzyme prodrug therapies. Advanced Drug Delivery Reviews 2017;118:65-77. [DOI: 10.1016/j.addr.2017.06.013] [Cited by in Crossref: 92] [Cited by in F6Publishing: 84] [Article Influence: 18.4] [Reference Citation Analysis]
90 Yang J, Li L, Kopeček J. Biorecognition: A key to drug-free macromolecular therapeutics. Biomaterials 2019;190-191:11-23. [PMID: 30391799 DOI: 10.1016/j.biomaterials.2018.10.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
91 Khera E, Thurber GM. Pharmacokinetic and Immunological Considerations for Expanding the Therapeutic Window of Next-Generation Antibody-Drug Conjugates. BioDrugs 2018;32:465-80. [PMID: 30132210 DOI: 10.1007/s40259-018-0302-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
92 Seijsing J, Yu S, Frejd FY, Höiden-Guthenberg I, Gräslund T. In vivo depletion of serum IgG by an affibody molecule binding the neonatal Fc receptor. Sci Rep 2018;8:5141. [PMID: 29572538 DOI: 10.1038/s41598-018-23481-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
93 Awwad S, Angkawinitwong U. Overview of Antibody Drug Delivery. Pharmaceutics 2018;10:E83. [PMID: 29973504 DOI: 10.3390/pharmaceutics10030083] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 12.3] [Reference Citation Analysis]
94 Sockolosky JT, Trotta E, Parisi G, Picton L, Su LL, Le AC, Chhabra A, Silveria SL, George BM, King IC, Tiffany MR, Jude K, Sibener LV, Baker D, Shizuru JA, Ribas A, Bluestone JA, Garcia KC. Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes. Science 2018;359:1037-42. [PMID: 29496879 DOI: 10.1126/science.aar3246] [Cited by in Crossref: 123] [Cited by in F6Publishing: 114] [Article Influence: 30.8] [Reference Citation Analysis]
95 Villa CH, Seghatchian J, Muzykantov V. Drug delivery by erythrocytes: "Primum non nocere". Transfus Apher Sci 2016;55:275-80. [PMID: 27856317 DOI: 10.1016/j.transci.2016.10.017] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
96 Sharma SK, Chow A, Monette S, Vivier D, Pourat J, Edwards KJ, Dilling TR, Abdel-Atti D, Zeglis BM, Poirier JT, Lewis JS. Fc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models. Cancer Res 2018;78:1820-32. [PMID: 29363548 DOI: 10.1158/0008-5472.CAN-17-1958] [Cited by in Crossref: 37] [Cited by in F6Publishing: 26] [Article Influence: 9.3] [Reference Citation Analysis]
97 Iyengar ARS, Gupta S, Jawalekar S, Pande AH. Protein Chimerization: A New Frontier for Engineering Protein Therapeutics with Improved Pharmacokinetics. J Pharmacol Exp Ther 2019;370:703-14. [DOI: 10.1124/jpet.119.257063] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
98 Costa F, Teixeira C, Gomes P, Martins MCL. Clinical Application of AMPs. Adv Exp Med Biol 2019;1117:281-98. [PMID: 30980363 DOI: 10.1007/978-981-13-3588-4_15] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 9.7] [Reference Citation Analysis]
99 Vivier D, Sharma SK, Adumeau P, Rodriguez C, Fung K, Zeglis BM. The Impact of FcγRI Binding on Immuno-PET. J Nucl Med 2019;60:1174-82. [PMID: 30733320 DOI: 10.2967/jnumed.118.223636] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
100 Betker JL, Angle BM, Graner MW, Anchordoquy TJ. The Potential of Exosomes From Cow Milk for Oral Delivery. J Pharm Sci 2019;108:1496-505. [PMID: 30468828 DOI: 10.1016/j.xphs.2018.11.022] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 10.5] [Reference Citation Analysis]
101 Andersen AHF, Riber CF, Zuwala K, Tolstrup M, Dagnæs-hansen F, Denton PW, Zelikin AN. Long-Acting, Potent Delivery of Combination Antiretroviral Therapy. ACS Macro Lett 2018;7:587-91. [DOI: 10.1021/acsmacrolett.8b00179] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
102 Qiu Y, Lv W, Xu M, Xu Y. Single chain antibody fragments with pH dependent binding to FcRn enabled prolonged circulation of therapeutic peptide in vivo. Journal of Controlled Release 2016;229:37-47. [DOI: 10.1016/j.jconrel.2016.03.017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]